Validation of economic and health outcomes simulation model of type 2 diabetes mellitus (ECHO-T2DM)

Journal of Medical Economics

Volumn 16, Issue 8, 2013, Pages 1007-1021

  Willis, Michael ^a   Asseburg, Christian ^b   He, Jianming ^c  

^a SWEDISH INSTITUTE FOR HEALTH ECONOMICS   (Sweden)

^b Esior Oy   (Finland)

^c JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Diabetes; Economic model; Validation

Indexed keywords

ARTICLE; CONVERGENT VALIDITY; ECONOMIC EVALUATION; EXTERNAL VALIDITY; FACE VALIDITY; FEEDBACK SYSTEM; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PREDICTION; SIMULATION; VALIDATION STUDY;

BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; COMORBIDITY; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; HUMANS; MODELS, ECONOMIC; REPRODUCIBILITY OF RESULTS;

EID: 84880553022     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2013.809352     Document Type: Article

References (41)

1. Drummond M, Schulper M, Torrance G, et al. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press; 2005
2. ADA. Guidelines for computer modeling of diabetes and its complications. Diabetes Care 2004;27:2262-5
3. Caro JJ, Briggs AH, Siebert U, et al. Modeling good research practices-Overview: A report of the ISPOR-SMDM modeling good research practices task force-1. Med Decis Making 2012;32:667-77
4. Willis M, Asseburg C, Borg S, et al. Cost-effectiveness of strict 'get to goal' treatment directives in the treatment of younger patients with newly diagnosed type 2 diabetes mellitus. 9th Annual ISPOR European Congress; September 18-19, 2010; Malmö, Sweden
5. Eastman RC, Javitt JC, Herman WH, et al. Model of complications of NIDDM. I. Model construction and assumptions. Diabetes Care 1997;20:725-34
6. Palmer AJ, Roze S, Valentine WJ, et al. The CORE diabetes model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004;20(Suppl 1):S5-26
7. Beale S, Bagust A, Shearer AT, et al. Cost-effectiveness of rosiglitazone combination therapy for the treatment of type 2 diabetes mellitus in the UK. Pharmacoeconomics 2006;24(Suppl 1):21-34
8. Eddy DM, Hollingworth W, Caro JJ, et al. Model transparency and validation: A report of the ISPOR-SMDM modeling good research practices task force-7. Med Decis Making 2012;32:733-43
9. The Mount Hood 4 Modeling Group. Computer modeling of diabetes and its complications: A report on the fourth Mount Hood challenge meeting. Diabetes Care 2004;30:1638-46
10. Mount Hood Challenge homepage. Available at: https://sites.google.com/ site/mounthoodchallenge/home [Last accessed 1 March 2013]
11. Brown JB, Palmer AJ, Bisgaard P, et al. The Mt. Hood challenge: cross-testing two diabetes simulation models. Diabetes Res Clin Pract 2000;50(Suppl 3):S57-64
12. Eastman RC, Javitt JC, Herman WH, et al. Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care 1997;20:735-44
13. Palmer AJ, The Mount Hood 5 modeling group. Computer modeling of diabetes and its complications: A report on the fifth Mount Hood challenge meeting. Value Health 2013;In press.
14. Palmer AJ, Roze S, Valentine WJ, et al. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Curr Med Res Opin 2004;20(Suppl 1):S27-40
15. Eddy DM, Schlessinger L. Validation of the Archimedes diabetes model. Diabetes Care 2003;26:3102-10
16. Clarke PM, Gray AM, Briggs A, et al. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom prospective diabetes study (UKPDS) outcomes model (UKPDS no. 68). Diabetologia 2004;47:1747-59
17. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
18. Klein R, Klein BE, Moss SE, et al. Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy. JAMA 1988;260:2864-71
19. Thomason MJ, Colhoun HM, Livingstone SJ, et al. Baseline characteristics in the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes. Diabetic Med 2004;21:901-5
20. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96
21. Gerstein HC, Bosch J, Pogue J, et al. Rationale and design of a large study to evaluate the renal and cardiovascular effects of an ACE inhibitor and vitamin E in high-risk patients with diabetes. The MICRO-HOPE study. Microalbuminuria, cardiovascular, and renal outcomes. Heart outcomes prevention evaluation. Diabetes Care 1996;19:1225-8
22. HOPE Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-9
23. Sasaki A, Uehara M, Horiuchi N, et al. A 15 year follow-up study of patients with non-insulin dependent diabetes mellitus (NIDDM) in Osaka, Japan. Long-term prognosis and causes of death. Diabetes Res Clin Pract 1996;34:47-55
24. Hoerger T, Segel J, Zhang P, et al. Validation of the CDC-RTI diabetes costeffectiveness model. RTI Press publication No. MR-0013-0909. Research Triangle Park, NC: RTI International, 2009. Available at: http://www.rti.org/ rtipress [Last accessed 1 March 2013]
25. Mueller E, Maxion-Bergemann S, Gultyaev D, et al. Development and validation of the Economic Assessment of Glycemic control and Long-term Effects of diabetes (EAGLE) model. Diabetes Technol Ther 2006;8:219-36
26. American Diabetes Association. Guidelines for computer modeling of diabetes and its complications. Diabetes Care 2004;27:2262-5
27. Simmons RK, Coleman RL, Price HC, et al. Performance of the UK prospective diabetes study risk engine and the Framingham risk equations in estimating cardiovascular disease in the EPIC-Norfolk cohort. Diabetes Care 2009;32: 708-13
28. Kengne AP, Patel A, Colagiuri S, et al. The Framingham and UK Prospective Diabetes Study (UKPDS) risk equations do not reliably estimate the probability of cardiovascular events in a large ethnically diverse sample of patients with diabetes: The Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR Controlled Evaluation (ADVANCE) study. Diabetologia 2010;53:821-31
29. van der Heijden AA, Ortegon MM, Niessen LW, et al. Prediction of coronary heart disease risk in a general, pre-diabetic, and diabetic population during 10 years of follow-up: accuracy of the Framingham, SCORE, and UKPDS risk functions: The Hoorn Study. Diabetes Care 2009;32:2094-8
30. Zhou H, Isaman DJ, Messinger S, et al. A computer simulation model of diabetes progression, quality of life, and cost. Diabetes Care 2005;28: 2856-63
31. Barhak J, Isaman DJ, Ye W, et al. Chronic disease modeling and simulation software. J Biomed Inform 2010;43:791-9
32. Wilk MB, Gnanadesikan R. Probability plotting methods for the analysis of data. Biometrika 1968;55:1-17
33. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59
34. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72
35. Knopp RH, d'Emden M, Smilde JG, et al. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care 2006;29:1478-85
36. Bagust A, Hopkinson PK, Maier W, et al. An economic model of the long-term health care burden of type II diabetes. Diabetologia 2001;44:2140-55
37. Brown JB, Russell A, Chan W, et al. The global diabetes model: User friendly version 3.0. Diabetes Res Clin Pract 2000;50(Suppl 3):S15-46
38. Bagust A, Evans M, Beale S, et al. A model of long-term metabolic progression of type 2 diabetes mellitus for evaluating treatment strategies. Pharmacoeconomics 2006;24(Suppl 1):5-19
39. Klein R, Klein BEK, Moss SE. Prevalence of microalbuminuria in older-onset diabetes. Diabetes Care 1993;16:1325-30
40. Dyck PJ, Kratz KM, Karnes, JL, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology 1993;43:817-24
41. Palumbo, PJ, Melton SJ. Peripheral vascular disease and diabetes. In: Harris MI, Cowie CC, Stern MP, et al., editors. Diabetes in America. Bethesda: National Institutes of Health; 1995:401-408